Young & Partners Biotech Financing Review and Outlook (June 21, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Young & Partners Chemical M&A Review and Outlook (June 5, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Young & Partners Pharma M&A Review and Outlook (June 2, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Young & Partners Biotech M&A Review and Outlook (June 2, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Biopharma M&A: Year in Review, Ripples Ahead (Pharmaceutical Executive, March 2023)
Young & Partners shares analysis of the global disruptions and uncertainties that have affected Biopharma M&A and the outlook for 2023.
Debt Financing to be difficult in 2023 (ICIS Chemical Business February 3 – February 9, 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed Stock Prices and Financings and the outlook for 2023.
Young & Partners Pharma and Biotech M&A Review and Outlook (January 20, 2023)
Proprietary data and analysis of 2022 and the current outlook.
Young & Partners Chemical M&A Review and Outlook (January 17, 2023)
Proprietary data and analysis of 2022 and the current outlook.
Disruptions to hit M&A, financing (ICIS Chemical Business December 2 – December 8, 2022)
Young & Partners shows that global disruptions and uncertainties are suppressing M&A, Stock Prices and Financings.
Chemical M&A trends shift down (ICIS Chemical Business August 26 – September 1, 2022)
Young & Partners shows that global disruptions and uncertainties are suppressing M&A, Stock Prices and Financings.